Artificial intelligence-derived biomarker predicts ADT benefit in prostate cancer subset

SAN FRANCISCO -- An artificial intelligence-derived digital pathology-based biomarker can help guide treatment decisions for men with localized intermediate-risk prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium. The biomarker (ArteraAI-Predict ADT) demonstrated that a majority of men treated with radiation therapy as part of a large randomized phase 3 trial did not require androgen derivation therapy and could have avoided the adverse events and costs associated with that treatment. This is the first validated predictive biomarker for the benefit of ADT with radiotherapy in localized intermediate-risk prostate cancer, according to researcher Daniel E. Spratt, MD, chair of the department of radiation oncology at University Hospitals Cleveland Medical Center. "This is a 10 out of 10. This is one of the most exciting things I've been a part of," Spratt told Healio.